

February 02, 2024

The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001
BSE Scrip Code: 543427

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, G Block,
Bandra - Kurla Complex
Bandra (East), Mumbai – 400051
NSE Symbol: MEDPLUS

Dear Sir/Madam,

Sub: Outcome of Board meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR") of the Company



Pursuant to Regulation 30 read with Regulation 33 of SEBI LODR and other applicable provisions, if any, we would like to inform that the Board of Directors at its meeting concluded just now on February 02, 2024 has *inter alia* approved the followings:

1. The un-audited standalone and consolidated financial results of the Company for the quarter ended December 31, 2023. The copy of the said quarterly financial result along with Limited Review Report issued by the B S R and Co, the Statutory Auditors of the Company is enclosed herewith.
2. Revision of Code of Conduct of the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015.

The meeting of the Board of Directors started at 02:30 PM and concluded at 4.45 PM. The copy of above communication shall also be available on the Company's website, BSE Ltd. & National Stock Exchange of India Limited.

You are requested to kindly take the same on records and disseminate the information on your website.

For MedPlus Health Services Limited


Manoj Kumar Srivastava
Company Secretary & Compliance Officer
FCS-7460




Encl. Copy of results and Limited Review Report

Limited Review Report on unaudited consolidated financial results of MedPlus Health Services Limited for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of MedPlus Health Services Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of 2 Subsidiaries included in the Statement, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 2,250.51 million and Rs. 7,216.04 million, total net profit after tax (before consolidation adjustments) of Rs. 12.85 million and Rs. 39.93 million and total comprehensive income (before consolidation adjustments) of Rs. 12.85 million and Rs. 39.93 million, for the quarter ended 31 December 2023 and for the period from 1 April 2023 to 31 December 2023 respectively, as considered in the Statement. These interim financial results have been reviewed by other auditor whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.



Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

Limited Review Report (Continued)

MedPlus Health Services Limited

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial results of 9 Subsidiaries which have not been reviewed, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 807.26 million and Rs. 2,880.89 million, total net profit after tax (before consolidation adjustments) of Rs. 2.66 million and Rs. 29.90 million and total comprehensive income (before consolidation adjustments) of Rs. 2.66 million and Rs 29.90 million, for the quarter ended 31 December 2023 and for the period from 1 April 2023 to 31 December 2023 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these financial results are not material to the Group.

Our conclusion is not modified in respect of this matter.

For B S R and Co

Chartered Accountants

Firm's Registration No.:128510W



Arpan Jain

Partner

Hyderabad

02 February 2024

Membership No.: 125710

UDIN:24125710BKFZNA8665

Limited Review Report (Continued)

MedPlus Health Services Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	MedPlus Health Services Limited	Holding Company
2	Optival Health Solutions Private Limited	Subsidiary
3	MHS Pharmaceuticals Private Limited	Subsidiary
4	Nova Sud Pharmaceuticals Private Limited	Subsidiary
5	Wynclark Pharmaceuticals Private Limited	Subsidiary
6	Kalyani Meditimes Private Limited	Subsidiary
7	Clearancekart Private Limited	Subsidiary
8	Sai Sridhar Pharma Private Limited	Subsidiary
9	Venkata Krishna Enterprises Private Limited	Subsidiary
10	Shri Banashankari Pharma Private Limited	Subsidiary
11	Deccan Medisales Private Limited	Subsidiary
12	Sidson Pharma Distributors Private Limited	Subsidiary
13	MedPlus Insurance Brokers Private Limited	Subsidiary

MedPlus Health Services Limited


CIN - L85110TG2006PLC051845

Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037

Statement of Unaudited Consolidated Financial Results for the Quarter and Nine month period ended December 31, 2023

(Rs. in Millions)

S. No.	Particulars	Quarter ended			Nine month period ended		Year ended
		December 31, 2023	September 30, 2023	December 31, 2022	December 31, 2023	December 31, 2022	March 31, 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
	Revenue from operations	14,414.72	14,085.89	11,903.14	41,343.57	33,045.93	45,575.76
	Other income	97.91	103.65	113.61	295.49	323.84	460.78
I	Total income	14,512.63	14,189.54	12,016.75	41,639.06	33,369.77	46,036.54
	Expenses						
	Cost of materials consumed	125.38	98.40	67.64	322.85	169.54	258.80
	Purchases of stock-in-trade	11,522.91	11,803.08	9,867.83	33,745.43	27,373.92	37,529.32
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(420.91)	(860.48)	(670.38)	(1,690.97)	(1,666.36)	(2,211.24)
	Employee benefits expense	1,595.29	1,577.92	1,438.04	4,649.19	3,965.34	5,451.29
	Finance costs	244.98	235.39	210.82	713.07	607.58	830.27
	Depreciation and amortisation expense	571.11	554.73	457.89	1,649.99	1,257.58	1,815.56
	Other expenses	674.25	616.06	482.78	1,834.92	1,363.08	1,890.91
II	Total expenses	14,313.01	14,025.10	11,854.62	41,224.48	33,070.68	45,564.91
III	Profit before tax (I-II)	199.62	164.44	162.13	414.58	299.09	471.63
	Tax expense						
	- Current tax	97.80	57.16	50.48	184.21	85.77	180.53
	- Deferred tax benefit	(35.23)	(38.16)	(22.16)	(89.79)	(22.14)	(209.95)
IV	Total tax expense / (benefit)	62.57	19.00	28.32	94.42	63.63	(29.42)
V	Profit after tax (III-IV)	137.05	145.44	133.81	320.16	235.46	501.05
	Other Comprehensive Income (OCI)						
	(i) Items that will not be reclassified to profit or loss						
	- Re-measurement gain / (loss) on employee defined benefit plan	15.51	28.46	(2.69)	43.97	4.93	4.61
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(2.99)	(5.69)	0.68	(8.68)	(1.21)	(1.27)
VI	Other comprehensive income / (loss) for the period/year, net of tax	12.52	22.77	(2.01)	35.29	3.72	3.34
VII	Total comprehensive income for the period/year (V+VI)	149.57	168.21	131.80	355.45	239.18	504.39
VIII	Profit for the period/year attributable to:						
	Shareholders of the Company	137.26	145.64	134.07	320.77	231.80	497.63
	Non-controlling interest	(0.21)	(0.20)	(0.26)	(0.61)	3.66	3.42
		137.05	145.44	133.81	320.16	235.46	501.05
IX	Total comprehensive income attributable to:						
	Shareholders of the Company	149.78	168.41	132.06	356.06	235.52	500.97
	Non-controlling interest	(0.21)	(0.20)	(0.26)	(0.61)	3.66	3.42
		149.57	168.21	131.80	355.45	239.18	504.39
X	Paid-up Capital						
	Equity Share Capital	239.07	238.70	238.60	239.07	238.60	238.61
XI	Other Equity						14,673.17
XII	Earnings per equity share (for the period not annualised)						
	Basic (In absolute Rs.)	1.15	1.22	1.20	2.69	2.16	4.17
	Diluted (In absolute Rs.)	1.14	1.21	1.20	2.67	2.16	4.17
XIII	Face value per share						
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00	2.00	2.00




B

**Segment information under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
for the Quarter and Nine month period ended December 31, 2023**

(Rs. In Millions)

Particulars	Quarter Ended			Nine month period ended		Year Ended
	December 31, 2023	September 30, 2023	December 31, 2022	December 31, 2023	December 31, 2022	March 31, 2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment revenue						
a. Retail	14,218.00	13,902.96	11,806.23	40,822.84	32,859.80	45,268.70
b. Diagnostic services	196.03	181.51	96.91	516.53	186.13	305.54
c. Others	0.69	1.42	-	4.20	-	1.52
Revenue from operations	14,414.72	14,085.89	11,903.14	41,343.57	33,045.93	45,575.76
2. Segment results profit / (loss)						
a. Retail	255.54	206.09	171.43	568.59	335.80	599.12
b. Diagnostic services	(85.36)	(77.32)	(62.79)	(258.32)	(208.60)	(294.50)
c. Others	(1.36)	(0.70)	(1.00)	(2.10)	(1.20)	(0.90)
Total	168.82	128.07	107.64	308.17	126.00	303.72
Less: Unallocable Finance cost	-	-	-	-	-	(8.81)
Add: Unallocable other income	30.80	36.37	54.49	106.41	173.09	176.72
Total profit before tax	199.62	164.44	162.13	414.58	299.09	471.63
3. Segment assets						
a. Retail	25,668.71	25,575.03	22,737.42	25,668.71	22,737.42	23,029.62
b. Diagnostic services	1,710.98	1,726.84	1,586.62	1,710.98	1,586.62	1,719.85
c. Unallocated	2,404.78	2,072.26	2,928.77	2,404.78	2,928.77	3,217.71
Total	29,784.47	29,374.13	27,252.81	29,784.47	27,252.81	27,967.18
4. Segment liabilities						
a. Retail	13,351.59	13,163.93	11,899.09	13,351.59	11,899.09	12,118.54
b. Diagnostic services	970.61	977.61	757.38	970.61	757.38	932.44
c. Unallocated	11.58	12.71	-	11.58	-	11.19
Total	14,333.78	14,154.25	12,656.47	14,333.78	12,656.47	13,062.17

P



Notes to the Unaudited consolidated financial results:

1. The above unaudited consolidated financial results of MedPlus Health Services Limited ('The Company') and its subsidiaries (together referred as 'The Group') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on February 02, 2024. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unqualified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:


(Rs. In Millions)

Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to December 31, 2023	Unutilised amount as on December 31, 2023*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	4,671.70	-
ii) General Corporate Purposes	1,111.03	448.53	662.50
Total	5,782.73	5,120.23	662.50

* The aforesaid unutilised proceeds of Rs. 662.50 million have been placed as fixed deposits with bank.

3. The Board of Directors of the Company, at their meeting held on January, 10 2023, have approved a Scheme of amalgamation (Scheme) between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary, with an appointed date of April 01, 2023. During the quarter, the Company has received approval from equity shareholders and trade creditors at their meeting held on December 15, 2023, pursuant to NCLT order dated November 07, 2023. The management has filed the final petition for approval under section 232 read with section 230 of the Companies Act, 2013 dated December 26, 2023.
4. During the year ended 31 March 2023, based on the assessment of the future taxable profitability of its subsidiary, Optival Health Solutions Private Limited, the Group had recognized deferred tax assets on unexpired portion of tax incentive available u/s 80JJAA amounting to Rs.97.39 million.
5. During the year ended 31 March 2023, the Chief Operating Decision Maker of the Group has carried out necessary change in the composition of its reportable segments. The said exercise has resulted in the Group identifying two reportable segments, i.e. (i) Retail trading of medicines and general items, and (ii) Diagnostic services. The comparative information as presented in the consolidated segment information have been restated to this effect in accordance with Ind AS 108.
6. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

For and on behalf of the Board of Directors of
MedPlus Health Services Limited


G.Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097



Place: Hyderabad
Date: February 02, 2024

Limited Review Report on unaudited standalone financial results of MedPlus Health Services Limited for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of MedPlus Health Services Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of MedPlus Health Services Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2023 and year to date results for the period from 1 April 2023 to 31 December 2023 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

Arpan Jain

Partner

Hyderabad

02 February 2024

Membership No.: 125710

UDIN:24125710BKFZNB1080

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

MedPlus Health Services Limited

CIN - L85110TG2006PLC051845

Registered Office: H.No:11-6-56, Survey No: 257 & 258/1, Opp: IDPL Railway Siding Road, Moosapet, Kukatpally, Hyderabad 500037

Statement of Unaudited Standalone Financial Results for the Quarter and Nine month period ended December 31, 2023

(Rs. in Millions)

S. No	Particulars	Quarter ended			Nine month period ended		Year ended
		December 31, 2023	September 30, 2023	December 31, 2022	December 31, 2023	December 31, 2022	March 31, 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
	Income						
	Revenue from operations	1,480.97	986.73	572.41	3,186.62	1,269.78	2,139.26
	Other income	18.23	17.65	40.66	53.95	136.98	162.39
I	Total income	1,499.20	1,004.38	613.07	3,240.57	1,406.76	2,301.65
	Expenses						
	Cost of materials consumed	125.37	101.19	67.28	325.56	168.63	257.77
	Purchases of stock-in-trade	1,015.71	625.31	357.53	2,063.26	769.69	1,314.91
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	10.06	(7.29)	(17.20)	(2.57)	(25.84)	(3.96)
	Employee benefits expense	112.92	108.81	73.99	319.31	182.92	281.45
	Finance costs	21.04	21.10	17.90	62.93	44.96	65.45
	Depreciation and amortisation expense	62.66	59.65	42.40	177.68	99.81	153.07
	Impairment reversals (net)	-	-	-	-	-	(69.44)
	Other expenses	109.02	95.99	53.36	287.21	156.58	226.54
II	Total expenses	1,456.78	1,004.76	595.26	3,233.38	1,396.75	2,225.79
III	Profit / (Loss) before tax (I-II)	42.42	(0.38)	17.81	7.19	10.01	75.86
	Tax expense						
	- Current tax	10.54	-	11.61	10.54	11.61	20.42
	- Deferred tax	-	-	-	-	-	-
IV	Total tax expense	10.54	-	11.61	10.54	11.61	20.42
V	Net Profit / (Loss) after tax (III-IV)	31.88	(0.38)	6.20	(3.35)	(1.60)	55.44
	Other comprehensive income						
	(i) Items that will not be reclassified to profit or loss						
	- Re-measurement gain / (loss) on employee defined benefit plan	3.66	5.84	-	9.50	0.12	(3.56)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
VI	Other comprehensive income / (loss) for the period / year, net of tax	3.66	5.84	-	9.50	0.12	(3.56)
VII	Total comprehensive income / (loss) for the period / year (V+VI)	35.54	5.46	6.20	6.15	(1.48)	51.88
VIII	Paid-up capital						
	Equity share capital	239.07	238.70	238.60	239.07	238.60	238.61
IX	Other Equity						11,174.17
X	Earnings / (Loss) per equity share (for the period not annualised)						
	Basic (In absolute Rs.)	0.27	(0.00)	0.15	(0.03)	0.08	0.46
	Diluted (In absolute Rs.)	0.27	(0.00)	0.15	(0.03)	0.08	0.46
XI	Face value per share						
	Equity shares (In absolute Rs.)	2.00	2.00	2.00	2.00	2.00	2.00



8

Notes to the Unaudited standalone financial results:

1. The above unaudited standalone financial results of MedPlus Health Services Limited ('The Company') have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("listing regulations") from time to time. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on February 02, 2024. These financial results have been subjected to limited review by the Statutory Auditors of the Company and the auditors have expressed and issued an unqualified review report on the same.
2. During the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021.

The utilization of IPO proceeds received by the Company (net of IPO related expense) is summarized below:

(Rs. In Millions)


Objects as per Prospectus	Planned utilisation as per Prospectus	Utilisation up to December 31, 2023	Unutilised amount as on December 31, 2023*
i) Investment in Subsidiary - Optival Health Solutions Private Limited towards their working capital requirements	4,671.70	4,671.70	-
ii) General Corporate Purposes	1,111.03	448.53	662.50
Total	5,782.73	5,120.23	662.50

* The aforesaid unutilised proceeds of Rs. 662.50 million have been placed as fixed deposits with bank.

3. As per Ind AS 108 'Operating segments', the Company has disclosed the segment information only as part of the consolidated financial results.
4. The Board of Directors of the Company, at their meeting held on January 10, 2023, have approved a Scheme of amalgamation (Scheme) between the Company and MHS Pharmaceuticals Private Limited (MHS), a wholly owned subsidiary, with an appointed date of April 01, 2023. During the quarter, the Company has received approval from equity shareholders and trade creditors at their meeting held on December 15, 2023, pursuant to NCLT order dated November 07, 2023. The management has filed the final petition for approval under section 232 read with section 230 of the Companies Act, 2013 dated December 26, 2023.
5. During the year ended 31 March 2023, the Company recognised provision for impairment of its investments and loans receivable (including interest) from Kalyani Meditimes Private Limited, a Subsidiary, to the tune of Rs.56.33 million. The Company, during the said period, has also reversed impairment provision made during the prior periods to the tune of Rs.125.77 million in respect of investments in another subsidiary, WynClark Pharmaceuticals Private Limited. These amounts were recorded/reversed pursuant to management assessment of the future cash flows of the underlying subsidiary Companies and their historic and projected profitability.
6. The above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com.

Φ

For and on behalf of the Board of Directors of
MedPlus Health Services Limited


G. Madhukar Reddy
Managing Director and Chief Executive Officer
DIN: 00098097



Place: Hyderabad
Date: February 02, 2024